KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Acadia Pharmaceuticals (ACAD) EBITDA Margin (2016 - 2025)

Acadia Pharmaceuticals has reported EBITDA Margin over the past 16 years, most recently at 20.46% for Q4 2025.

  • Quarterly results put EBITDA Margin at 20.46% for Q4 2025, down 7959.0% from a year ago — trailing twelve months through Dec 2025 was 2.74% (down 2136.0% YoY), and the annual figure for FY2025 was 2.74%, down 2136.0%.
  • EBITDA Margin for Q4 2025 was 20.46% at Acadia Pharmaceuticals, down from 12.83% in the prior quarter.
  • Over the last five years, EBITDA Margin for ACAD hit a ceiling of 97.23% in Q4 2022 and a floor of 97.88% in Q1 2022.
  • Median EBITDA Margin over the past 5 years was 4.61% (2023), compared with a mean of 2.18%.
  • Biggest five-year swings in EBITDA Margin: skyrocketed 5961bps in 2021 and later crashed -8211bps in 2023.
  • Acadia Pharmaceuticals' EBITDA Margin stood at 69.29% in 2021, then surged by 40bps to 97.23% in 2022, then crashed by -84bps to 15.12% in 2023, then skyrocketed by 291bps to 59.13% in 2024, then crashed by -135bps to 20.46% in 2025.
  • The last three reported values for EBITDA Margin were 20.46% (Q4 2025), 12.83% (Q3 2025), and 12.24% (Q2 2025) per Business Quant data.